PI3K Inhibitors in Cancer Therapy: Recent Advances and Future Perspectives
Medicinal Research Reviews · 15.11.2026
DOI: 10.1002/med.70132 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 15.11.2026. Verfasst von He-Nan Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Die Arbeit nennt 116 Literaturangaben. Gefördert von: Liaoning Province Science and Technology Plan Joint Program (Natural Science Foundation-General Program).
Abstract (Originalsprache)
The phosphoinositide 3‐kinase (PI3K) signaling pathway has emerged as a well‐established therapeutic target in oncology, driving substantial efforts toward the rational development of small‐molecule inhibitors. Over the last 20 years, diverse structural categories of PI3K inhibitors have been engineered through structure‐based design and medicinal chemistry refinement, encompassing pan‐PI3K inhibitors, isoform‐selective agents, and dual PI3K/mTOR inhibitors. Notably, several compounds including idelalisib, alpelisib, and copanlisib have gained regulatory approval, demonstrating the clinical significance of targeting specific PI3K isoforms in particular cancer settings. However, despite these achievements, the clinical application of first‐generation inhibitors has been constrained by off‐target toxicities, limited therapeutic windows, and unfavorable pharmacokinetic profiles. These limitations have spurred continued investigation into next‐generation inhibitors featuring enhanced selectivity, diminished toxicity, and improved drug‐like properties. This review summarizes recent progress in PI3K inhibitor development from 2021 to the present, which will guide the further development of next‐generation therapeutic agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Neurology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
- China Medical University, Shenyang, Liaoning, China.
ORCID-Profile: He-Nan Liu, Qingqing Chen
Förderung
- Liaoning Province Science and Technology Plan Joint Program (Natural Science Foundation-General Program)
Zitieren
APA
Liu, H. N., Guo, C., Zhu, Y., Liu, Q., Li, H., Yin, J., Cao, P., Zhang, H., & Chen, Q. (2026). PI3K Inhibitors in Cancer Therapy: Recent Advances and Future Perspectives. Medicinal Research Reviews. https://doi.org/10.1002/med.70132
Vancouver
Liu HN, Guo C, Zhu Y, Liu Q, Li H, Yin J, et al. PI3K Inhibitors in Cancer Therapy: Recent Advances and Future Perspectives. Medicinal Research Reviews. 2026. doi:10.1002/med.70132
BibTeX
@article{Liu2026,
author = {Liu, He-Nan and Guo, Cuishan and Zhu, Ying and Liu, Qifang and Li, Hui and Yin, Jiao and Cao, Pin and Zhang, Huijie and Chen, Qingqing},
title = {PI3K Inhibitors in Cancer Therapy: Recent Advances and Future Perspectives},
journal = {Medicinal Research Reviews},
year = {2026},
doi = {10.1002/med.70132}
}
EUVIMED